Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- No More Problems with Speed or Quality of Clinical Trials in Japan: Korosho's WG
October 19, 2009
- Meiji Seika Aims at Top-3 Position in CNS
October 19, 2009
- R&D NEWS IN BRIEF
October 19, 2009
- Daiichi Sankyo to Make Vaccines One of Its Core Businesses
October 19, 2009
- Sandoz's Somatropin Equivalent to Original Product: Mr Nakamichi
October 19, 2009
- New Drugs Account for 13% of Total Sales: Novartis
October 19, 2009
- JSGM to Propose Standard Prescription Ordering Form
October 19, 2009
- Sales Force Effectiveness Summit Japan 2009
October 19, 2009
- Pharmacists Should Play Key Role in Promoting Use of Generics: JSGM Seminar
October 19, 2009
- BUSINESS NEWS IN BRIEF
October 19, 2009
- Korosho Urges Nat'l Univ. Hospitals to Use More Generics
October 19, 2009
- Discussions on Medical Fees Halted
October 19, 2009
- Japan's First DPP-4 Inhibitor Sitagliptin to Be Approved
October 12, 2009
- Gov't to Procure Flu Vaccines for 77 Million Persons
October 12, 2009
- Eisai Applies for Non-Erosive GERD in Japan as Additional Indication for Pariet
October 12, 2009
- SURVEY／20% of Respondents Reluctant to Receive New-Type Flu Vaccines
October 12, 2009
- Eisai, Abbott Japan Apply for Humira for Crohn's Disease
October 12, 2009
- SEMINAR／Patients' Awareness of RA Treatment Insufficient: Prof. Yamamoto
October 12, 2009
- Parliamentary Secretary Shinya Adachi to Evaluate Chuikyo Membership
October 12, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 12, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…